Randomized control clinical trial to evaluate protective effects of combination therapy of ARB and DDP-4 inhibitor on pancreatic beta cell functio
Not Applicable
- Conditions
- Type 2 diabetes mellitus complicated with essential hypertension
- Registration Number
- JPRN-UMIN000007595
- Lead Sponsor
- Kyoto Prefectural University School of Medicine Department of Cardiovascular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded from the study if there is any evidence of type 1 diabetes, treatment with insulin, GLP-1 analog, and other hypoglycemic agent except for sulfonylurea, renal failure (serum creatinine: more than 1.5 mg/dl for male, 1.3 mg/dl for female), severe liver dysfunction, pregnancy and past history of diabetic coma within 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ratio of pro-insulin to insulin, HOMA-beta
- Secondary Outcome Measures
Name Time Method HbA1c, insulin sensitivity(HOMA-IR), body weight, blood pressure